## **Benzamide Derivative 1**

| Cat. No.:<br>CAS No.:<br>Molecular Formula:<br>Molecular Weight:<br>Target:<br>Pathway:<br>Storage: | HY-U00415<br>108226-05-7<br>C <sub>22</sub> H <sub>34</sub> ClN <sub>3</sub> O <sub>3</sub><br>423.98<br>Dopamine Receptor; mAChR<br>GPCR/G Protein; Neuronal Signaling<br>Please store the product under the recommended conditions in the Certificate of<br>Analysis. |  |
|---|---|--|
|---|---|--|

| BIOLOGICAL ACTIVITY       |   |  |
|---------------------------|---|--|
| biological activity       |   |  |
| Description               | Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be<br>useful in treatment of gastrointestinal disorders.  |  |
| IC <sub>50</sub> & Target | Dopamine, mACh receptor <sup>[1]</sup>  |  |
| In Vitro                  | Substituted benzamides have been shown to possess a number of pharmacological properties most of which are related to their ability to antagonize the central and peripheral effects of dopamine and/or facilitate the release of acetylcholine on to muscarinic receptors in the gastrointestinal smooth muscle. This has led to their successful clinical use as antiemetic and in the treatment of a wide range of gastrointestinal disorders of somatic, psychosomatic and iatrogenic origin <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |  |

## REFERENCES

[1]. Noverola V, et al. Preparation and formulation of N-heterocyclyl-substituted benzamides useful in treatment of gastrointestinal disorders. EP0213775A1.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA



## Product Data Sheet